Frank Stephen Hodi
Harvard University · 1,583 works · 163,538 citations · h-index 155
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- High-throughput oncogene mutation profiling in human cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients